Live Breaking News & Updates on Nd Malaise There Was No Increase In Reactogenicity Younger 12 To Lt 15 Years Old Adolescents Compared Older 18 New Safety Signal Observed Through The Placebo Controlled Portion Of Study 17 Year Population

Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea GAITHERSBURG, Md., Aug. 12, 2022 /PRNewswire/ Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that partner, SK bioscience, has received a Post Approval Change Application approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17. "Today's approval in South Korea is an important step in ensuring broad global access to a protein-based vaccine option," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "We are pleased to collaborate with SK b ....

South Korea , United States , Giovanna Chandler , Jaeyong Ahn , Erika Schultz , Stanleyc Erck , Korean Ministry Of Food , Drug Administration , Prnewswire Novavax Inc , Exchange Commission , Administration Of Nuvaxovid , European Union , Serum Institute Of India , Novavax Inc , Post Approval Change Application , Korean Ministry , Drug Safety , Chief Executive Officer , Name Use , Product Characteristics , Package Leaflet , Prescribing Information , Important Safety Information , Serum Institute , Vaccine Efficacy Novavax Trial , New England Journal ,